Cargando…
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
Background: In epithelial ovarian cancer (EOC), 15–20% of the tumors do not respond to first-line chemotherapy (paclitaxel with platinum-based therapy), and in recurrences this number increases. Our aim is to determine the feasibility of cell proliferation assays of tumor cells isolated from maligna...
Autores principales: | den Ouden, Judith E., Zaman, Guido J.R., Dylus, Jelle, van Doornmalen, Antoon M., Mulder, Winfried R., Grobben, Yvonne, van Riel, Wilhelmina E., de Hullu, Joanne A., Buijsman, Rogier C., van Altena, Anne M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733621/ https://www.ncbi.nlm.nih.gov/pubmed/33346216 http://dx.doi.org/10.18632/oncotarget.27827 |
Ejemplares similares
-
Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1
por: Grobben, Yvonne, et al.
Publicado: (2023) -
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
por: Grobben, Yvonne, et al.
Publicado: (2021) -
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
por: Kooijman, Jeffrey J., et al.
Publicado: (2022) -
Pharmacological validation of TDO as a target for Parkinson’s disease
por: Perez‐Pardo, Paula, et al.
Publicado: (2021) -
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158
por: Grobben, Yvonne, et al.
Publicado: (2019)